Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients

Giuseppe Derosa,^{1,2,6} Arrigo F. G. Cicero,³ Anna Carbone,⁴ Fabrizio Querci,⁵ Elena Fogari,¹ Angela D'Angelo,¹ and Pamela Maffioli¹

Retraction to: Inflammation (2014) 37(1):154–162
DOI: 10.1007/s10753-013-9724-x

This article has been retracted at the request of the Editor-in-Chief.

The authors have published results from exactly the same clinical study and patient population in 6 separate articles, without referencing the publications in any of the later articles:

1. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'angelo, A., Maffioli, P. 2013. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. *Clinical and Experimental Hypertension* 35: 301–307. doi:10.3109/10641963.2012.721841.
2. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P. 2013. Effects of an olmesartan/

amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. *Journal of Clinical Pharmacy and Therapeutics* 38: 48–55. doi:10.1111/jcpt.12021.

3. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P. 2013. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. *Journal of the American Society of Hypertension* 7: 32–39. doi:10.1016/j.jash.2012.11.006.
4. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P. 2013. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. *Expert Opinion on Drug Safety* 12: 621–629. doi:10.1517/14740338.2013.816674.
5. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P. 2014. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. *Inflammation* 37: 154–162. doi:10.1007/s10753-013-9724-x.
6. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P. 2014. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. *European Journal of Pharmaceutical Sciences* 51: 26–33. doi:10.1016/j.ejps.2013.08.031.

In addition, the article in *Inflammation* contains results published especially in articles 2 and 6, which is the main reason for retraction of the article in *Inflammation*.

The publisher apologizes for the inconvenience caused.

The online version of the original article can be found at doi: <http://dx.doi.org/10.1007/s10753-013-9724-x>.

¹ Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, P.le C. Golgi 2, 27100 Pavia, Italy

² Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, Pavia, Italy

³ Aging and Kidney Diseases, “G. Descovich” Atherosclerosis Study Center, University of Bologna, Bologna, Italy

⁴ Hospital Center of Diabetes, Sant'Angelo Lodigiano, Lodi, Italy

⁵ Ospedale Pesenti Fenaroli, Alzano Lombardo, Bergamo, Italy

⁶ To whom correspondence should be addressed at Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, P.le C. Golgi 2, 27100 Pavia, Italy. E-mail: giuseppe.derosa@unipv.it